Rosalind Advisors’s aTyr Pharma ATYR Stock Holding History

Rosalind Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,570,200	Closed	-$4.47M	–	48
2025 Q3	$4.47M	Buy	1,570,200 +1,347,200	+604%	+$6.1M	1.53%	22
2025 Q2	$271K	Buy	+223,000	New	+$877K	0.13%	34

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rosalind Advisors's ATYR Position: Q1 2026 in Review

Rosalind Advisors sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 1,039,080 shares — an estimated $13.6M sold.

Rosalind Advisors first reported a position in ATYR in Q3 2025 and held it in 2 quarters. The position peaked at $13.6M in Q4 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

Rosalind Advisors reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
Rosalind Advisors sold 1,039,080 aTyr Pharma shares in Q1 2026, an estimated $13.6M.
Rosalind Advisors first reported a position in aTyr Pharma in Q3 2025 and held it in 2 quarters.
Rosalind Advisors's aTyr Pharma position peaked at $13.6M in Q4 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.